The USPTO published patent application US20260090996A1 for a delayed-release oral pharmaceutical composition for inflammatory bowel disease (IBD) treatment. The invention involves a layered formulation with a mesalamine core layer, hyaluronan layer, and at least one coating layer designed for targeted colonic delivery. The patent claims the specific combination and configuration of these layers for therapeutic use.

No compliance actions are required from pharmaceutical manufacturers, healthcare providers, or other entities. This is a patent application publication, not a regulatory requirement or enforcement action. Entities developing similar delayed-release formulations for IBD may wish to conduct freedom-to-operate analyses to assess potential infringement risks. The patent application provides public notice of the claimed invention for competitive intelligence purposes.